A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty

Phase 3

Completed

Conditions: Postoperative Pain

Interventions: Drug: SKY0402
Drug: Bupivacaine HCl

Registration Number: NCT00745290

Lead Sponsor: Pacira Pharmaceuticals, Inc

Brief Summary: The primary objective is to demonstrate that SKY0402 is superior when compared to bupivacaine HCl in the management of postoperative pain for patients undergoing total knee arthroplasty.

Detailed Description: The primary objective is to demonstrate the superiority of SKY0402, compared with bupivacaine HC1, with respect to the extent and duration of the analgesic effect achieved by a single intraoperative administration of the study drug via local infiltration in subjects undergoing total knee arthroplasty (TKA).

The secondary objectives are to evaluate additional efficacy parameters and characterize the safety profile of SKY0402 in comparison with bupivacaine HCl.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 245

Inclusion Criteria

Male or female, ≥18 years of age at the Screening Visit.
Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.
American Society of Anesthesiology (ASA) Physical Classification System class 1-4.
Able and willing to comply with all study visits and procedures.
Able to speak, read, and understand the language of the informed consent form, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
Willing and capable of providing written informed consent.

Exclusion Criteria

Pregnancy, nursing, or planning to become pregnant during the study or within one month after dosing.
Use of any of the following medications within the times specified before surgery:
- Long-acting opioid medication within 3 days.
- Any opioid medication within 24 hours.
Concurrent painful physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site being administered study drug (e.g., significant pain from other joints, chronic neuropathic pain, concurrent contralateral TKA, concurrent foot surgery, etc.), which have the potential to confound the postoperative study assessments.
Body weight less than 60 kilograms (~132 pounds).
Contraindication to any of the pain-control agents planned for postoperative use (e.g., acetaminophen, morphine, oxycodone, ketorolac).
Contraindication to epinephrine, such as concurrent administration of ergot-type drugs, monoamine oxidase (MAO) inhibitors or antidepressants of triptoline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.

In addition, the subject will be ineligible to receive study drug if he or she meets the following criterion during surgery:
Any clinically significant event or condition uncovered during surgery (e.g., excessive bleeding), which occurs before study drug administration, that might render the subject medically unstable or complicate the subject's postoperative course.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SKY0402	SKY0402	Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
Bupivacaine HCl	Bupivacaine HCl	Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration

Primary Outcome Measures

Name	Time	Method
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores	through 72 hours post surgery	The subject's pain intensity was assessed with activity (NRS-A), while actively flexing the involved knee from the maximum extension point to the maximum flexion point possible. The subject responded to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain did you have while bending your knee?"

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events Through 96 Hours and Serious Adverse Events Through 30 Days	through 30 days

Trial Locations

Locations (19): Physicans Clinical Research Corp.
🇺🇸
Laguna Hills, California, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Accurate Clinical Trials, Inc.
🇺🇸
Laguna Hills, California, United States
Cedars of Sinai Medical Center
🇺🇸
Los Angeles, California, United States
West Alabama Research, Inc.
🇺🇸
Birmingham, Alabama, United States
Horizon Research Group, Inc., Alabama Orthopaedic Clinic
🇺🇸
Mobile, Alabama, United States
Sun Health Research Institute, Core Institute
🇺🇸
Sun City West, Arizona, United States
Drug Research and Analysis Corporation
🇺🇸
Montgomery, Alabama, United States
Scripps
🇺🇸
La Jolla, California, United States
Insall Scott Kelly Institute
🇺🇸
New York, New York, United States
Ilumina Clinical Associates
🇺🇸
Johnstown, Pennsylvania, United States
Atlanta Knee and Sports Medicine
🇺🇸
Decatur, Georgia, United States
CTMG, Inc.
🇺🇸
Greenville, North Carolina, United States
Duke University Medical Center
🇺🇸
Raleigh-Durham, North Carolina, United States
Research Associates of Jackson
🇺🇸
Jackson, Tennessee, United States
Ohio State University Medical Center
🇺🇸
Columbus, Ohio, United States
Allegheny Pain Management
🇺🇸
Altoona, Pennsylvania, United States
Texas Orthopedic Specialists, PA
🇺🇸
Grapevine, Texas, United States
Memorial Hermann City Hospital
🇺🇸
Houston, Texas, United States